The XINDI Study: A Randomized Phase III Clinical Trial Evaluating the Efficacy and Safety of Safinamide as Add-On Therapy to Levodopa in Chinese Patients with Parkinson's Disease with Motor Fluctuations.

CNS Drugs · 2022 · PMC9641300 · PMID 36346534

Europe PMC DOI

hedged sentence

0.8901

closest p · 17.8× alpha

0.8901

boldest claim

The sentences

did not reach statistical significancep = 0.8901not close (p > 0.1)

Therefore, despite NRS scores being numerically greater in the safinamide group versus the placebo group at the end of the study, the change did not reach statistical significance ( p = 0.8901, 95% CI − 0.440, + 0.382).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.